Cerebrolysin : The Next Evolution of Medicine

Product Information

Sharma et al (2010) Cerebrolysin reduces blood-cerebrospinal fluid barrier permeability change, brain pathology, and functional deficits following traumatic brain injury in the rat https://www.ncbi.nlm.nih.gov/pubmed/20633118 Liang S, Li Z, Yan H, Pei X (2001) The efficacy of Cerebrolysin in multi-infarct dementia. Heilongjiang Med Pharm 24(5):75 N. M. Bornstein et al., “Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials,” Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol., vol. 39, no. 4, pp. 629–640, Apr. 2018, doi: 10.1007/s10072-017-3214-0. Wong GK, Zhu XL, Poon WS (2005) Beneficial effect of cerebrolysin on moderate and severe head injury patients: result of a cohort study. Acta Neurochir Suppl 95:59–60. https://doi.org/10.1007/3-211-32318-x_13

A clinical trial performed on more than 200 patients regarding the efficacy of Cerebrolysin in patients with stroke showed that it can improve cognition and motor function in post-stroke patients, which can be determined by several lab tests. In this clinical trial, patients were administered with Cerebrolysin, 72 hours after stroke and continued for 21 days. [iii] Side Effects of Cerebrolysin: Chen S-D, Yang J-L, Hwang W-C, Yang D-I (2018) Emerging roles of sonic hedgehog in adult neurological diseases: neurogenesis and beyond. Int J Mol Sci 19(8). https://doi.org/10.3390/ijms19082423 Despite its prevalence and societal impact, there is no definitive, proven pharmacological treatment for VaD. Potential interventions may be considered at a number of levels: primary prevention, secondary prevention, symptomatic treatments, and disease‐modifying or curative approaches ( O'Brien 2006). The currently available data on the treatment of vascular risk factors does not prove a benefit in primary and secondary prevention ( Moorhouse 2008). Trials of monotherapies such as antiplatelet agent or statins for the prevention or treatment of VaD are also equivocal ( McGuinness 2014; O'Brien 2015; Chu 2018). Recent meta‐analysis of longitudinal Xiao S, Heqin Y, Peifen Y, Luning W, Jianjun J, Xin M, Feng B, Jie L, Chunxie W, Zhihua D, Mingyi Z, Wenzhen X, Yinglu G, Cui M, Daping W, Binhua S (2000) Efficacy of FPF 1070 (Cerebrolysin) in patients with Alzheimer’s disease: a multicentre, randomised, double-blind, placebo-controlled trial. Clin Drug Investig 19(1):43–53 Alvarez XA, Sampedro C, Figueroa J, Tellado I, Gonzalez A, Garcia-Fantini M, Cacabelos R, Muresanu D, Moessler H (2008) Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury. J Neural Transm (Vienna) 115(5):683–692. https://doi.org/10.1007/s00702-008-0024-9Muresanu DF, Ciurea AV, Gorgan RM, Gheorghita E, Florian SI, Stan H, Blaga A, Ianovici N, Iencean SM, Turliuc D, Davidescu HB, Mihalache C, Brehar FM, Mihaescu AS, Mardare DC, Anghelescu A, Chiparus C, Lapadat M, Pruna V, Mohan D, Costea C, Costea D, Palade C, Bucur N, Figueroa J, Alvarez A (2015) A retrospective, multi-center cohort study evaluating the severity- related effects of cerebrolysin treatment on clinical outcomes in traumatic brain injury. CNS Neurol Disord Drug Targets 14(5):587–599. https://doi.org/10.2174/1871527314666150430162531 Alvarez XA, Lombardi VR, Corzo L et al. (2000) Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects. J Neural Transm Suppl 59, 315-328.

Cerebrolysin has indication-specific dosing. The most common regime for improving brain function is IM injections of 5 ml daily. The course of treatment is 4 weeks unless otherwise prescribed by your attending physician. Vascular dementia is a common form of dementia caused by poor blood flow to the brain. There are currently no proven and licenced treatments for vascular dementia. Cerebrolysin is a medicine that is made from pig's brains and given as an injection. In some countries, Cerebrolysin is used as a treatment for vascular dementia. A previous summary from 2013 considered all studies of Cerebrolysin and vascular dementia. A definitive conclusion as to whether Cerebrolysin was beneficial could not be made.

All ACH/e-Check payments will be made payable to:

Authentic Cerebrolysin ampoules for injection are available at CosmicNootropic. We offer the most popular forms: Cerebrolysin 5ml and Cerebrolysin 10ml ampoules as well as other volumes depending on the purpose of use. Cerebrolysin is a combination of peptides and neurotrophins for enhancing the regeneration of neurons, neural plasticity, and neural protection during neurological illnesses, such as dementia and traumatic brain injuries. It is a neuropeptide drug formed from a series of biochemical and enzymatic reactions on porcine brain proteins. The ultimate product that is formed after a series of reactions has a low molecular weight and increased ability to cross the blood-brain barrier. Schwab et al (1997) Morphofunctional effects of moderate forebrain ischemia combined with short-term hypoxia in rats – protective effects of Cerebrolysin https://www.ncbi.nlm.nih.gov/pubmed/9085071 Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z, Cerebrolysin Acute Stroke Treatment in Asia I (2012) Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke 43(3):630–636. https://doi.org/10.1161/STROKEAHA.111.628537